Schizophrenia bulletin · 2026
Variability and Magnitude of Choline Levels Across the Psychosis Spectrum: A Meta-analysis.
СтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fanshawe Jack B, Watson Cameron J, Mancini Valentina, Cohen Matthew, Koçyiğit Doğukan, Bohra Rijul, Zauchenberger Chambrez-Zita, Varvari Ioana, Farid Anna, Perez-Rodriguez Violeta, Gifford George, Pillinger Toby, Beck Katherine, Jauhar Sameer, McGuire Philip, McCutcheon Robert A
Аннотация
BACKGROUND AND HYPOTHESIS: Animal, post-mortem, and pharmacological studies suggest altered choline levels in psychosis. Proton magnetic resonance spectroscopy (1H-MRS) may allow in vivo investigation of the cholinergic system. This meta-analysis examined the magnitude and variability of 1H-MRS choline across the psychosis spectrum.
STUDY DESIGN: Following a pre-registered protocol (CRD42023403879), we searched MEDLINE, EMBASE, and PsycINFO for studies reporting 1H-MRS choline levels in individuals with psychosis, clinical high risk (CHR) states, and healthy controls. Standardized mean differences (SMDs) and log coefficient of variation ratios were pooled using random-effects meta-analysis, stratified by brain region and clinical subgroup. Meta-regression examined associations with imaging and clinical parameters.
STUDY RESULTS: We included 165 studies comprising 5178 patients and 4269 controls. Choline levels were elevated in people with psychosis in the anterior cingulate cortex (ACC: SMD = 0.23, CI 0.12-0.33), medial prefrontal cortex (mPFC: SMD = 0.12, CI 0.01-0.23), and dorsolateral prefrontal cortex (dlPFC: SMD = 0.15, CI 0.01-0.28). Elevations were also seen in CHR cohorts (ACC: SMD 0.19, CI 0.03-0.36; mPFC: SMD 0.36, CI 0.16-0.57), with the largest effects in treatment-resistant schizophrenia (ACC: SMD 0.65, CI 0.38-0.91; dlPFC: SMD 1.13, CI 0.65-1.60). Increased choline variability was observed in the dlPFC in psychosis cohorts and the mPFC and temporal lobe in CHR groups.
CONCLUSIONS: This is the largest meta-analysis of 1H-MRS choline in psychosis to date. Increased variability in psychosis and greater differences in treatment-resistant cohorts suggest increased choline levels might identify a subgroup who do not respond to dopamine antagonist treatment.
STUDY DESIGN: Following a pre-registered protocol (CRD42023403879), we searched MEDLINE, EMBASE, and PsycINFO for studies reporting 1H-MRS choline levels in individuals with psychosis, clinical high risk (CHR) states, and healthy controls. Standardized mean differences (SMDs) and log coefficient of variation ratios were pooled using random-effects meta-analysis, stratified by brain region and clinical subgroup. Meta-regression examined associations with imaging and clinical parameters.
STUDY RESULTS: We included 165 studies comprising 5178 patients and 4269 controls. Choline levels were elevated in people with psychosis in the anterior cingulate cortex (ACC: SMD = 0.23, CI 0.12-0.33), medial prefrontal cortex (mPFC: SMD = 0.12, CI 0.01-0.23), and dorsolateral prefrontal cortex (dlPFC: SMD = 0.15, CI 0.01-0.28). Elevations were also seen in CHR cohorts (ACC: SMD 0.19, CI 0.03-0.36; mPFC: SMD 0.36, CI 0.16-0.57), with the largest effects in treatment-resistant schizophrenia (ACC: SMD 0.65, CI 0.38-0.91; dlPFC: SMD 1.13, CI 0.65-1.60). Increased choline variability was observed in the dlPFC in psychosis cohorts and the mPFC and temporal lobe in CHR groups.
CONCLUSIONS: This is the largest meta-analysis of 1H-MRS choline in psychosis to date. Increased variability in psychosis and greater differences in treatment-resistant cohorts suggest increased choline levels might identify a subgroup who do not respond to dopamine antagonist treatment.